Megamarket Liquid Biopsy: Guardant Health Emerges as a Winner Stock!
Reading Time: 1 minute
I've been discussing Guardant Health extensively in the Tenbagger Forum since early 2020. Back then, the stock was trading around 20 USD. The stock is speculative, but the market potential is enormous. The company is a pioneer in the field of liquid biopsy, employing innovative blood tests for cancer diagnostics, therapy selection, monitoring, and early detection. In the third quarter, Guardant achieved a significant milestone: the company surpassed an annual revenue rate of over 1 billion USD for the first time and exceeded expectations with a...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
